Vaximm AG, a subsidiary of OSR Health, announced it will publish clinical data from two studies on VXM01, an oral DNA vaccine targeting VEGFR-2, in recurrent glioblastoma patients. The vaccine showed safety, immune activation, and dose-dependent effects, supporting its potential as a cancer treatment. These findings build on previous positive results in pancreatic cancer and will guide future clinical development. Full results will be shared soon in a peer-reviewed journal.
Greg Abel, Warren Buffett's successor as CEO of Berkshire Hathaway, began his leadership by significantly reducing the company's investment in Chevron. At the same time, he introduced a virtual monopoly company into Berkshire's top five holdings, sig...
Galaxy Digital has committed $5 million to improve Bitcoin's resistance to potential quantum computing attacks. This move addresses concerns that future quantum computers could break Bitcoin's cryptographic security, posing a risk to its integrity. T...
On July 31, 2026, Shell plc repurchased a total of 1,530,000 shares for cancellation across different trading venues, including the London Stock Exchange and Euronext Amsterdam. This buyback is part of Shell's existing share repurchase program announ...
Curium has agreed to acquire Lantheus for up to $8 billion in cash, offering Lantheus shareholders $102.50 per share at closing plus up to $12 per share in contingent value rights based on future performance. The merger combines Curium's global thera...
Douglas Dynamics reported record second quarter 2026 results with net sales up 10% to $214.6 million and adjusted EBITDA rising 5% to $44.6 million. The company saw strong pre-season orders, especially in its Work Truck Attachments segment, driving a...
